Clinical trial
Study of Epratuzumab in Systemic Lupus Erythematosus
NCT00382837 · UCB Pharma, Industry · Withdrawn
Key facts
| NCT number | NCT00382837 |
|---|---|
| Title | Study of Epratuzumab in Systemic Lupus Erythematosus |
| Official title | A Phase III Multi-Center, OpenLabel, Follow-Up Study to Assess the Safety & Efficacy of Epratuzumab in Patients With Acute Severe SLE Flares Excluding the Renal or Neurologic Systems |
| Lead sponsor | UCB Pharma, Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Systemic Lupus Erythematosus |
| Intervention type | Drug |
| Interventions | Epratuzumab |
| Enrollment | 0 |
| Start date | Jan 1, 2007 |
| First posted | Oct 2, 2006 |
| Last update posted | May 21, 2014 |
| Countries | Belgium, Brazil, Canada, Czechia, France, Germany, Hungary, Italy, Netherlands, Slovakia, Spain, United Kingdom and 1 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: